Grants - Illinois - Designated Grants - 2014

Paul J. Hergenrother, Ph.D.

Funded by UNDEFEATED in honor of Chicago Blackhawks and Darlene Shaw

The experimental therapeutic PAC-1, when combined with FDA-approved drugs for metastatic breast cancer, has been found to give a highly synergistic effect on the killing of the breast cancer cells.  Given that PAC-1 is already being evaluated in a Phase 1 trial in cancer patients (NCT02355535), these results suggest future combination trials for the treatment of metastatic breast cancer patients. 

Continue Jim’s Legacy and Donate Today!

100% of direct donations benefit cancer research and programs. 

Donate Today

Ready to Join?

Donate Monthly and Become an MVP Today!

100% of direct donations benefit cancer research and programs.

Start a Monthly Gift